Daniel Kreatsoulas

ORCID: 0000-0002-9727-7019
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Head and Neck Surgical Oncology
  • Meningioma and schwannoma management
  • Pituitary Gland Disorders and Treatments
  • Glioma Diagnosis and Treatment
  • Cerebrospinal fluid and hydrocephalus
  • Neurosurgical Procedures and Complications
  • Brain Metastases and Treatment
  • Spinal Fractures and Fixation Techniques
  • Vascular Malformations Diagnosis and Treatment
  • Advanced Radiotherapy Techniques
  • Trigeminal Neuralgia and Treatments
  • Advanced MRI Techniques and Applications
  • Management of metastatic bone disease
  • Sinusitis and nasal conditions
  • Facial Nerve Paralysis Treatment and Research
  • Intracranial Aneurysms: Treatment and Complications
  • Dispute Resolution and Class Actions
  • Carbon Nanotubes in Composites
  • Genomic variations and chromosomal abnormalities
  • Cardiac, Anesthesia and Surgical Outcomes
  • Medical Imaging and Analysis
  • Cardiovascular Health and Disease Prevention
  • Botulinum Toxin and Related Neurological Disorders
  • Ear Surgery and Otitis Media
  • Immune cells in cancer

The Ohio State University
2020-2025

The Ohio State University Wexner Medical Center
2020-2025

Neurological Surgery
2020-2025

Recent studies have shown the importance of dynamic tumor microenvironment (TME) in high-grade gliomas (HGGs). In particular, myeloid cells are known to mediate immunosuppression glioma; however, it is still unclear if play a role low-grade glioma (LGG) malignant progression. Here, we investigate cellular heterogeneity TME using single-cell RNA sequencing murine model that recapitulates progression LGG HGG. LGGs show increased infiltrating CD4

10.1016/j.celrep.2023.112197 article EN cc-by-nc-nd Cell Reports 2023-03-01

Abstract Background Malignant gliomas are a therapeutic challenge and remain nearly uniformly fatal. While new targeted chemotherapeutic agentsagainst malignant glioma have been developed in vitro, these putative therapeutics not translated into successful clinical treatments. The lack of effectiveness can be the result ineffective biologic strategies, heterogeneous tumor targets and/or poortherapeutic distribution to cells using conventional nervous system delivery modalities...

10.1007/s11060-023-04552-8 article EN cc-by Journal of Neuro-Oncology 2024-01-01

Abstract Purpose Papillary craniopharyngioma is a rare entity, demonstrating BRAF-V600E mutations in approximately 95% of patients. Recently, phase 2 trial patients treated with surgery and BRAF/MEKi demonstrated 91% reduction residual tumor volume. This study allowed for additional treatments at the discretion treatment team without reporting subsequent rates endocrinopathy or visual decline. We aimed to evaluate possibility employing need adjuvant radiotherapy therapies. Methods A...

10.1007/s11060-025-04969-3 article EN cc-by Journal of Neuro-Oncology 2025-02-20

Introduction: Papillary craniopharyngioma is a rare entity, demonstrating BRAF-V600E mutations in approximately 95% of patients. Recently, phase-2 trial patients treated with surgery and BRAF/MEKi demonstrated 91% reduction residual tumor volume. This study allowed for additional treatments at the discretion treatment team without reporting subsequent rates endocrinopathy or visual decline. We aimed to evaluate possibility employing need adjuvant radiotherapy therapies.

10.1055/s-0045-1803541 article EN Journal of Neurological Surgery Part B Skull Base 2025-02-01

BACKGROUND AND OBJECTIVE: Maximal safe resection of newly diagnosed glioblastoma (GBM) optimizes clinical outcomes. For patients who receive biopsy or subtotal (STR), early repeat (ERR) to improve extent can be considered but is controversial. Oncological outcomes undergoing ERR for residual GBM receiving upfront at least near-total were compared. METHODS: This case-control study including with treated a single institution identified 3 treatment groups: (1) underwent STR (<95%...

10.1227/neu.0000000000003381 article EN Neurosurgery 2025-02-21

Spontaneous CSF leaks are rare, their diagnosis is often delayed, and they can precipitate meningitis. Craniotomy the historical "gold standard" repair for these leaks. An endonasal endoscopic approach (EEA) offers potentially less invasiveness lower surgical morbidity than a traditional craniotomy but must yield same success. A paucity of data exists studying EEA as primary management spontaneous

10.3171/2019.12.jns192891 article EN Journal of neurosurgery 2020-03-06

The endoscopic endonasal approach (EEA) has evolved into a mainstay of skull base surgery over the last two decades, but publications examining intraoperative and perioperative complications this technique remain scarce. A prior landmark series 800 patients reported during first era EEA (1998-2007), parallel to development many now-routine techniques technologies. authors examined single-institution more than 1000 consecutive neurosurgical procedures performed since 2010, elucidate safety...

10.3171/2020.11.jns202494 article EN Journal of neurosurgery 2021-08-06

BACKGROUND AND OBJECTIVES: Cranial robotics are a burgeoning field of neurosurgery. To date, all cranial robotic systems described have been computerized, arm-based instruments that take up significant space in the operating room. The Medtronic Stealth Autoguide robot has smaller room footprint and offers multiaxial, frame-based surgical targeting. authors set out to define characteristics novel platform for brain biopsy large patient cohort. METHODS: Patients who underwent stereotactic...

10.1227/ons.0000000000000999 article EN Operative Neurosurgery 2023-11-17

OBJECTIVE A growing body of literature suggests that preoperative opioid exposure is an independent predictor poor outcomes in surgical patients. No data exist on use and craniotomies/craniectomies. The objective this study was to determine the impact 90-day adverse events after craniotomy or craniectomy. METHODS single-center retrospective cohort 2445 patients undergoing a craniotomy/craniectomy between January 1, 2013, October 2018, conducted. Baseline demographics, pre- postoperative...

10.3171/2024.1.jns23615 article EN Journal of neurosurgery 2024-03-09

OBJECTIVE The objective of this study was to assess the feasibility, accuracy, effectiveness, and safety an MRI-compatible frameless stereotactic ball-joint guide array (BJGA) as a platform for cannula placement convection-enhanced delivery (CED). METHODS authors analyzed clinical imaging data from consecutive patients with aromatic l -amino acid decarboxylase (AADC) deficiency who underwent infusion adeno-associated virus (AAV) containing AADC gene (AAV2-AADC). RESULTS Eleven (7 females, 4...

10.3171/2020.6.jns201564 article EN Journal of neurosurgery 2020-10-23

Operative management of craniovertebral junction (CVJ) osteomyelitis has traditionally been extracranial and focused on debriding the infection. In select patients, endoscopic endonasal approach (EEA) with a focus additional resection versus debridement may be preferred. The goal this study is to present authors' experience EEA gross or subtotal for treatment at CVJ describe their technique in context literature.Two patients 6 detailed case reports literature were identified mean age 58.9...

10.3171/case22290 article EN other-oa Journal of Neurosurgery Case Lessons 2023-01-02

Introduction: Surgical approaches to tumors of the upper anterior cervical spine require a thorough knowledge regional anatomy, consideration extent disease, intent surgery, and what reconstruction stabilization options are available. Often, for lower spine, true paramedian sufficient. However, lesions involving superior most vertebral bodies pose unique access challenges. We present case study patient with recurrent C2–C3 chordoma that underwent aggressive resection using Bernard George...

10.1055/s-0044-1780211 article EN Journal of Neurological Surgery Part B Skull Base 2024-02-01

Objective: Management of OGM has changed significantly with the advances in extended endonasal approaches (EEA), which is an excellent approach for patients anosmia since allows early devascularization and minimizes retraction on frontal lobes. Resection can be performed by both EEA and/or open techniques based tumor size patient's preoperative olfaction status. Early devascularization, debulking, detachment from surrounding brain make transcribriform attractive strategy OGM. However, nearly...

10.1055/s-0044-1779962 article EN Journal of Neurological Surgery Part B Skull Base 2024-02-01

Objective: The expanded endonasal transpterygoid approach (EETA) is used to access the middle and posterior fossa through pterygoid process. Traditionally, eustachian tube (ET) was resected during EETA, which often required subsequent myringotomy for inner ear drainage. Anterolateral transposition of ET proposed decrease potential morbidity associated with resection. However, a comparison resection versus regarding need has not been reported.

10.1055/s-0044-1779851 article EN Journal of Neurological Surgery Part B Skull Base 2024-02-01

Abstract INTRODUCTION CD74, a chaperone associated with the major histocompatibility complex class II (MHC-II), plays crucial role in assembling and transporting MHC-II molecules on cellular surface. Beyond its physiological function antigen presentation, CD74 is negative regulator of inflammation, dysregulation inflammatory disorders cancer. Notably, tumor stem cells release macrophage migration inhibitory factor (MIF) to trigger immunosuppressive signaling tumor-infiltrating immune cells,...

10.1093/neuonc/noae165.0608 article EN Neuro-Oncology 2024-11-01

Abstract Intraoperative magnetic resonance imaging (iMRI) allows assessment of extent resection during surgery for high-grade glioma (HGG). In most cases, contrast-enhancing areas noted on iMRI indicate residual tumor. However, false positives may occur, leading to inappropriate additional and patient morbidity. The rate pattern positive findings in have not been fully described. We analyzed surgical patients undergoing HGG determine factors linked with potential contrast enhancement. A...

10.1093/neuonc/noae165.0837 article EN Neuro-Oncology 2024-11-01
Coming Soon ...